More Bavarian Nordic Shareholders Unite Against PE Takeover

A growing coalition of Bavarian Nordic A/S shareholders, representing nearly 10% of the company's capital, is actively opposing the private equity takeover bid from Nordic Capital and Permira, signaling potential hurdles for the proposed acquisition of the Danish vaccine maker.

Analysis

A significant coalition of Bavarian Nordic A/S shareholders, representing nearly 10% of the company's share capital, has formalized its opposition to a proposed private equity buyout from Nordic Capital and Permira. This coordinated resistance, organized through the Danish Shareholders Association and involving over 3,300 investors, introduces a material hurdle for the acquisition. Such a substantial bloc of dissenting shareholders suggests that the current bid may be perceived as undervaluing the Danish vaccine maker, creating uncertainty around the deal's successful completion. The PE firms may now be compelled to either increase their offer to secure shareholder approval or risk the transaction failing, injecting significant event-driven volatility into the stock.

Key Decisions for Investors

• Investors should closely monitor communications from both the private equity bidders and the shareholder group, as the organized opposition from a block owning nearly 10% of the company could force a revised, higher offer or lead to the deal's termination.
• Event-driven and merger arbitrage funds must reassess the probability of the deal's completion, as the coordinated shareholder pushback introduces significant execution risk that could widen the arbitrage spread but also increases the chance of the bid failing.
• Consider the stock's valuation on a standalone basis, as the failure of the bid is now a more tangible possibility, which would likely cause the share price to revert to trading on its fundamental merits rather than the proposed acquisition premium.